Get the Stockscreener App
3.05
0.99%
0.03
After Hours:
3.05
Lexaria Bioscience Corp stock is traded at $3.05, with a volume of 114.35K.
It is up +0.99% in the last 24 hours and down -21.99% over the past month.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
See More
Previous Close:
$3.02
Open:
$3.01
24h Volume:
114.35K
Relative Volume:
0.65
Market Cap:
$48.22M
Revenue:
$276.00K
Net Income/Loss:
$-6.09M
P/E Ratio:
-2.6991
EPS:
-1.13
Net Cash Flow:
$-5.99M
1W Performance:
-3.48%
1M Performance:
-21.99%
6M Performance:
-15.98%
1Y Performance:
+205.03%
1-Day Range:
$2.92
$3.10
1-Week Range:
$2.91
$3.21
52-Week Range:
$0.85
$6.85
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Lexaria Bioscience Corp Stock (LEXX) Latest News
Lexaria Advances Oral Diabetes Treatment Study - TipRanks
LEXXWLexaria Bioscience Corp. Warrant Latest Stock News & Market Updates - StockTitan
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 - StockTitan
Stocks of Lexicon Pharmaceuticals Inc (LXRX) are poised to climb above their peers - SETE News
XTX Topco Ltd Raises Stock Holdings in Lantronix, Inc. (NASDAQ:LTRX) - Defense World
Victory Capital Management Inc. Acquires 13,972 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Great Point Partners LLC Purchases New Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Understanding LXRX’s book value per share for better investment insights - US Post News
Upward Trajectory: Lexicon Pharmaceuticals Inc (LXRX) Posts a Slidee, Closing at 1.58 - The Dwinnex
Light & Wonder price target lowered to $90 from $92 at Susquehanna - TipRanks
Bearish block trade of LIFETECH SCI(01302) 1.3M shares at $1.5, $1.95M turnover - AASTOCKS.com
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs - MSN
Why Is Lattice Semiconductor (LSCC) Stock Rocketing Higher Today By Stock Story - Investing.com Canada
Financial Analysis: Lexaria Bioscience (NASDAQ:LEXX) & Xeris Biopharma (NASDAQ:XERS) - Defense World
Lexaria (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program - Barchart
Lexaria Bioscience : Corporate Presentation - Marketscreener.com
Best-selling drugs in pill form: How Lexaria plans to make it big on weight-loss wave - Kursiv Media
The Globe and Mail - The Globe and Mail
Lexaria Bioscience Corp (LEXX-Q) QuotePress Release - The Globe and Mail
Lexaria (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO - Barchart
Lexaria Bioscience Corp WT (LEXXW-Q) QuotePress Release - The Globe and Mail
Lexaria appoints Richard Christopher as CEO - MSN
LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan
Lexaria Bioscience names new CEO, outlines severance terms - Investing.com
Lexaria Bioscience appoints new CEO Richard Christopher - Investing.com
Lexaria Bioscience appoints Richard Christopher as new CEO - Investing.com
Lexaria Bioscience appoints new CEO Richard Christopher - Investing.com India
Lexaria Bioscience appoints Richard Christopher as new CEO - Investing.com India
Lexaria Bioscience Appoints New CEO for Growth Era - TipRanks
Lexaria Bioscience Ushers in New Leadership and Focus - TipRanks
Lexaria Bioscience names new CEO, outlines severance terms By Investing.com - Investing.com UK
Lexaria Bioscience appoints Richard Christopher as new CEO By Investing.com - Investing.com Canada
Lexaria Bioscience appoints new CEO Richard Christopher By Investing.com - Investing.com Canada
Lexaria Releases Strategic Letter from the Outgoing CEO - TheNewswire.ca
Lexaria Releases Strategic Letter from the Outgoing CEO - AccessWire
Lexaria Welcomes Industry Veteran as New CEO - Troy Media
Lexaria Bioscience appoints Richard Christopher as new CEO By Investing.com - Investing.com UK
Lexaria Welcomes Industry Veteran as New CEO - Yahoo Finance
Work at The Globe - The Globe and Mail
Lexaria (NASDAQ: LEXX) Announces Agreement to Evaluate DehydraTECH(TM) in Pre-Clinical Setting - Barchart
Lexaria partners with PharmaCO for drug delivery tech evaluation - Investing.com India
Lexaria Bioscience Advances Drug Delivery with PharmaCO Partnership - TipRanks
Lexaria partners with PharmaCO for drug delivery tech evaluation By Investing.com - Investing.com Australia
Lexaria partners with PharmaCO for drug delivery tech evaluation By Investing.com - Investing.com UK
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research - ACN Newswire
Lexaria Bioscience (LEXX) Experiences Continued Stock Surge - Stocks Telegraph
Lexaria reports progress in drug delivery study By Investing.com - Investing.com Canada
Lexaria reports progress in drug delivery study - Investing.com
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules - StockTitan
Short Interest in Lexaria Bioscience Corp. (NASDAQ:LEXXW) Expands By 766.7% - Defense World
Lexaria reports higher absorption in drug study - Investing.com India
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):